Comparison of Fluticasone Propionate and Budesonide
Dose Equivalency Based on Guidelines
- The National Asthma Education and Prevention Program (NAEPP) provides dose equivalency tables, establishing that fluticasone propionate 110 mcg is approximately equivalent to budesonide 200-220 mcg, with fluticasone being roughly 1.5-2 times more potent per microgram than budesonide, for adults and children 1, 2, 3
- For adults, the low daily dose of fluticasone propionate (HFA/MDI) 110 mcg/puff is 88-264 mcg, while the low daily dose of budesonide (DPI) 90, 180, or 200 mcg/inhalation is 180-600 mcg, according to the EPR-3 asthma guidelines 1, 3
- For children (5-11 years), fluticasone 88-176 mcg daily (low dose) corresponds to budesonide 180-400 mcg daily (low dose), as per the EPR-3 asthma guidelines 1, 3
Potency Ratio Evidence
- The American College of Allergy, Asthma, and Immunology recommends considering the potency ratio of fluticasone propionate to budesonide, which is approximately 1.50:1 to 1.75:1 (95% CI 1.10:1-2.43:1), based on clinical trial data 2, 4
Clinical Application
- The National Asthma Education and Prevention Program (NAEPP) suggests that fluticasone propionate 110 mcg twice daily (220 mcg/day total) is clinically similar to budesonide 200 mcg twice daily (400 mcg/day total), but the preparations are not interchangeable on a mcg-per-puff basis and require dose adjustment when switching 1, 3
- The American Academy of Allergy, Asthma, and Immunology recommends proper inhaler technique and consideration of delivery device characteristics when prescribing fluticasone propionate or budesonide 1
- The National Asthma Education and Prevention Program (NAEPP) advises caution when using potent CYP3A4 inhibitors like ritonavir or ketoconazole with fluticasone and budesonide, as they are metabolized by CYP3A4 enzymes 3
- The American College of Allergy, Asthma, and Immunology recommends minimizing local side effects (cough, dysphonia, oral thrush) with spacer devices and mouth rinsing after use 1, 3
- The National Asthma Education and Prevention Program (NAEPP) suggests monitoring patient response and titrating to the minimum effective dose once control is achieved 1, 3